Dodging a dogma: Is treating beyond progression beneficial?

Aung Naing; Razelle Kurzrock

doi:10.1007/s00280-013-2123-z

Dodging a dogma: Is treating beyond progression beneficial?

Aung Naing, Razelle Kurzrock

Investigational Cancer Therapeutics

Research output: Contribution to journal › Short survey › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	1385-1386
Number of pages	2
Journal	Cancer chemotherapy and pharmacology
Volume	71
Issue number	5
DOIs	https://doi.org/10.1007/s00280-013-2123-z
State	Published - May 2013

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

Access to Document

10.1007/s00280-013-2123-z

Cite this

@article{fb5aba64d88843f3abbd12728f85d318,

title = "Dodging a dogma: Is treating beyond progression beneficial?",

author = "Aung Naing and Razelle Kurzrock",

year = "2013",

month = may,

doi = "10.1007/s00280-013-2123-z",

language = "English (US)",

volume = "71",

pages = "1385--1386",

journal = "Cancer chemotherapy and pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "5",

}

TY - JOUR

T1 - Dodging a dogma

T2 - Is treating beyond progression beneficial?

AU - Naing, Aung

AU - Kurzrock, Razelle

PY - 2013/5

Y1 - 2013/5

UR - http://www.scopus.com/inward/record.url?scp=84877926446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877926446&partnerID=8YFLogxK

U2 - 10.1007/s00280-013-2123-z

DO - 10.1007/s00280-013-2123-z

M3 - Short survey

C2 - 23443308

AN - SCOPUS:84877926446

SN - 0344-5704

VL - 71

SP - 1385

EP - 1386

JO - Cancer chemotherapy and pharmacology

JF - Cancer chemotherapy and pharmacology

IS - 5

ER -

Dodging a dogma: Is treating beyond progression beneficial?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this